Daphne Brooks Stewart MD MS (She/Her)
Breast Cancer, Gynecologic Cancer
Physician
Join to View Full Profile
USC Norris Comprehensive Cancer Center, Keck School of Medicine1441 Eastlake Ave, NTT3440Los Angeles, CA 90033
Phone+1 323-865-3000
Fax+1 323-865-5528
Dr. Stewart is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1999 - 2002
University of Southern California/LACUSC Medical CenterInternship, Transitional Year, 1998 - 1999
Columbia University Vagelos College of Physicians and SurgeonsClass of 1998
Certifications & Licensure
CA State Medical License 1999 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body Start of enrollment: 2019 Aug 02
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2021 Oct 20
Publications & Presentations
PubMed
- First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.Nehal J Lakhani, Daphne Stewart, Debra L Richardson, Lauren E Dockery, Linda Van Le
Journal for Immunotherapy of Cancer. 2025-01-11 - Impact of Structural Racism and Social Determinants of Health on Disparities in Breast Cancer Mortality.Mary Falcone, Bodour Salhia, Chanita Hughes Halbert, Evanthia T Roussos Torres, Daphne Stewart
Cancer Research. 2024-12-02 - 2 citationsUGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan.Megan H Wong, Veronica C Jones, Wai Yu, Linda D Bosserman, Sayeh M Lavasani
Cancer Medicine. 2024-08-01
Press Mentions
- Health Care Providers Battle Burnout in Fight Against Covid-19November 11th, 2020
SEIU 1991 Launches Video Series Honoring ‘Healthcare Heroes’ at Jackson HealthJune 9th, 2020
Clinical Challenges: CDK4/6 Inhibitors in Breast CancerJune 12th, 2019
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
